TY - JOUR
T1 - Outcome of allogeneic hematopoietic stem cell transplantation for mycosis fungoides and Sézary syndrome
AU - Mori, Takehiko
AU - Shiratori, Souichi
AU - Suzumiya, Junji
AU - Kurokawa, Mineo
AU - Shindo, Motohiro
AU - Naoyuki, Uchida
AU - Katsuto, Takenaka
AU - Miyamoto, Toshihiro
AU - Morishige, Satoshi
AU - Hirokawa, Makoto
AU - Fukuda, Takahiro
AU - Atsuta, Yoshiko
AU - Suzuki, Ritsuro
N1 - Funding Information:
T.M. received research funding from MSD, Novartis Pharma, LSI Medience, Medical and Biological Laboratories, and Asahi Kasei Corporation, and personal fees from Pfizer, MSD, Janssen Pharma, Sumitomo Dainippon Pharma, Novartis Pharma, Kyowa Kirin, Chugai Pharmaceutical, Shionogi and Co., Japan Blood Products Organization, Takeda Pharmaceutical, Ono Pharmaceutical, Shire, Eisai, and Astellas Pharma. J.S. received research funding Celgene, Kyowa Hakko Kirin, Chugai‐Roche, Eisai, Takeda, Celltrion, SymBio, Astellas, Ono, AstraZeneca, Ootsuka, Taiho, Mundi, and Dainihon‐Sumitomo, and personal fees from Chugai‐Roche, Celgene, Janssen, Takeda, Bristol Myers Squibb, Dainihon‐Sumitomo, Nihonshinyaku, Taiho, Abbie, Eisai, Celgene, Zenyaku, Novartis, Eli Lilly, AstraZeneca, Pfizer, Bioverativ, and MSD. Y.A. received an honorarium from Mochida Pharmaceutical, Meiji Seika Pharma, Chugai Pharmaceutical, and Kyowa Kirin. R.S. received honoraria from Bristol‐Meyers Squibb, Novartis, Kyowa‐Hakko Kirin, Chugai Pharmaceuticals, Shionogi, Takeda, Meiji Seika Pharma, MSD, Ohtsuka, Sawai, Celgene, Sumitomo Dainippon, Eisai Pharmaceuticals, Alexion Pharma, Sanofi, Ono Pharma, and Janssen, and a consultancy from Gilead Sciences, Abbvie, Mundi Pharma, and Jazz Pharma.
Funding Information:
The authors would like to thank all the physicians and data managers at each transplant center and the staff members of the Japanese Data Center for Hematopoietic Cell Transplantation. This work was supported in part by the Practical Research Project for Allergic Diseases and Immunology (Research Technology of Medical Transplantation) from the Japan Agency for Medical Research and Development, AMED, under grant number 19ek0510023h0002.
Publisher Copyright:
© 2020 John Wiley & Sons Ltd
PY - 2020/8/1
Y1 - 2020/8/1
N2 - Although allogeneic hematopoietic stem cell transplantation (HSCT) has been reported to provide prolonged remission of relapsed/refractory mycosis fungoides (MF) and Sézary syndrome (SS), its role has not been fully evaluated. Here, the outcomes of allogeneic HSCT for patients with MF/SS were retrospectively evaluated by using the registry database of the Japan Society for Hematopoietic Cell Transplantation. Forty-eight patients were evaluable and enrolled in the analysis. Median age was 45.5 years. Eighteen patients (38%) received myeloablative conditioning, and 33 (69%) received HSCT from an alternative donor. Disease status was complete or partial response in 25% of the patients and relapsed or refractory in the others. At the time of analysis, 18 patients were alive, with a median follow-up of 31.0 months (range, 3.8-31.1). Three-year overall survival (OS) and progression-free survival (PFS) were 30% (95%CI, 16-45%) and 19% (95%CI, 9-31%), respectively. Disease progression was not observed later than 17 months after transplantation. Both disease status and performance status at transplant significantly affected OS and PFS. Although our findings suggest that allogeneic HSCT provides long-term PFS in patients with MF/SS, the timing of transplantation should be decided carefully based on the disease status and the patient's condition in order to improve the outcome.
AB - Although allogeneic hematopoietic stem cell transplantation (HSCT) has been reported to provide prolonged remission of relapsed/refractory mycosis fungoides (MF) and Sézary syndrome (SS), its role has not been fully evaluated. Here, the outcomes of allogeneic HSCT for patients with MF/SS were retrospectively evaluated by using the registry database of the Japan Society for Hematopoietic Cell Transplantation. Forty-eight patients were evaluable and enrolled in the analysis. Median age was 45.5 years. Eighteen patients (38%) received myeloablative conditioning, and 33 (69%) received HSCT from an alternative donor. Disease status was complete or partial response in 25% of the patients and relapsed or refractory in the others. At the time of analysis, 18 patients were alive, with a median follow-up of 31.0 months (range, 3.8-31.1). Three-year overall survival (OS) and progression-free survival (PFS) were 30% (95%CI, 16-45%) and 19% (95%CI, 9-31%), respectively. Disease progression was not observed later than 17 months after transplantation. Both disease status and performance status at transplant significantly affected OS and PFS. Although our findings suggest that allogeneic HSCT provides long-term PFS in patients with MF/SS, the timing of transplantation should be decided carefully based on the disease status and the patient's condition in order to improve the outcome.
UR - http://www.scopus.com/inward/record.url?scp=85080996489&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85080996489&partnerID=8YFLogxK
U2 - 10.1002/hon.2719
DO - 10.1002/hon.2719
M3 - Article
C2 - 32011008
AN - SCOPUS:85080996489
SN - 0278-0232
VL - 38
SP - 266
EP - 271
JO - Hematological Oncology
JF - Hematological Oncology
IS - 3
ER -
